Cytokinetics Inc (CYTK)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

280 EAST GRAND AVENUE SOUTH SAN FRANCISCO, CA 94080

Focuses on the discovery, development and commercialization of novel small molecule drugs that target the cytoskeleton. As of March 2006, the company has small moleclue drug candidates in clinical development, and two in preclinical development.

Data as of 2020-08-09
Market Cap1.514 Billion Shares Outstanding70.394 Million Avg 30-day Volume1.07 Million
P/E Ratio Dividend Yield EPS-2.23
Price/Sales100.329 Price cash flow ratio2715.5 Price free cash flow ratio-20.8
Book Value-0.65 Price to Tangible Book-33.12 Alpha0.02
Short Interest Ratio % Short Interest to Float R-squared0.132688
BETA1.45724 52-week High/Low29.2 / 7.725 Stddev0.168225
View SEC Filings from CYTK instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 3 2 (0.13%)
13F Filers holding this stock: 145 40 (2.62%)
Aggregate 13F shares on 03/31/2020: 55.721 Million 29.539 Million
Aggregate 13F shares on 12/31/2019: 55.019 Million 29.049 Million
Percent change: 1.27% 1.69%
Funds creating new positions: 23 8
Funds Adding to an existing position: 59 17
Funds closing out their position: 15 12
Funds reducing their position: 40 11
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CYTK (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CYTK BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

123.2 Thousand total shares from 21 transactions

Exercise Derivative Conversion (M)

121.6 Thousand total shares from 20 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

EASTERN CAPITAL LTD

PORTFOLIO SERVICES LTD.

DART KENNETH BRYAN

  • 10% Owner
8,629,693 2020-08-07 0

BLUM ROBERT I PRESIDENT & CEO

  • Officer
  • Director
309,034 2020-08-05 19

BARBARI SHARON

  • Director
0 2020-08-03 0

SCHLOSSBERG MARK A SVP - LEGAL & GENERAL COUNSEL

  • Officer
30,000 2020-07-29 2

GAGE L PATRICK

  • Director
0 2020-07-28 4

SMITH SANDFORD D

  • Director
0 2020-07-15 11

MALIK FADY IBRAHAM EVP RESEARCH & DEVELOPMENT

  • Officer
155,034 2020-07-09 9

PARSHALL B LYNNE

  • Director
67,464 2020-07-01 3

COSTA SANTO J

  • Director
0 2020-06-22 4

WIERENGA WENDALL

  • Director
0 2020-06-19 2

KAYE EDWARD M. MD

  • Director
0 2020-06-11 4

SCHMERTZLER MICHAEL

  • 10% Owner
802,005 2020-06-05 0

HOMCY CHARLES J CHAIRMAN OF PHARMACEUTICALS

  • Officer
  • Director
0 2020-06-02 0

MCDADE MARK

  • Director
34,692 2020-05-27 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
480,432 2020-05-21 3

HENDERSON JOHN T

  • Director
982 2020-05-19 6

MCDOWELL CARYN GORDON CHIEF LEGAL & ADM. OFFICER

  • Officer
0 2020-05-14 0

CALIFF ROBERT

  • Director
0 2020-05-13 4

CRAGG DAVID SVP HUMAN RESOURCES

  • Officer
139,098 2020-03-06 4

JAW CHING SVP FINANCE & CFO

  • Officer
73,165 2020-03-06 3

WONG ROBERT VP, CHIEF ACCOUNTING OFFICER

  • Officer
13,004 2020-03-06 1

RODDY PETER S SVP FINANCE & CAO

  • Officer
21,520 2018-02-27 0

MORGAN BRADLEY PAUL SVP DRUG DISCOVERY & EARLY DEV

  • Officer
46,441 2017-08-31 0

DOW STEPHEN M

  • Director
307,190 2017-07-18 0

WOLFF ANDREW A SVP & CMO

  • Officer
47,255 2017-02-28 0

CHARPENTIER BONNIE SVP REGULATORY & COMPLIANCE

  • Officer
29,004 2017-02-28 0

SCHNIEDERS ELISABETH SR. VP, BUSINESS DEVELOPMENT

  • Officer
43,919 2017-02-28 0

GILBERT DENISE

  • Director
0 2015-07-10 0

EASTERN CAPITAL LTD

  • 10% Owner
14,303,071 2012-06-20 0

SPUDICH JAMES A

  • Director
180,600 2011-05-18 0

MORGANS DAVID J JR EVP-PRECLINICAL R&D

  • Officer
42,000 2011-02-28 0

HEIDRICH A GRANT III

  • Director
0 2011-01-03 0

SABRY JAMES H

  • FORMER EXECUTIVE CHAIRMAN
No longer subject to file 2010-06-03 0

RABSON MICHAEL SVP BUSINESS DEV/LEGAL & GC

  • Officer
20,043 2009-12-18 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-08-05 M 5,000 $6.00 a 309,868 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-08-05 M 5,000 d 89,434 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-08-05 S 5,000 $22.12 d 304,868 309,034.00 direct yes

SCHLOSSBERG MARK A - Officer SVP - LEGAL & GENERAL COUNSEL

2020-07-29 M 10,000 $7.03 a 40,000 30,000.00 direct yes

SCHLOSSBERG MARK A - Officer SVP - LEGAL & GENERAL COUNSEL

2020-07-29 M 10,000 d 45,244 30,000.00 direct yes

SCHLOSSBERG MARK A - Officer SVP - LEGAL & GENERAL COUNSEL

2020-07-29 S 10,000 $23.07 d 30,000 30,000.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-07-28 M 5,000 $6.00 a 309,868 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-07-28 M 5,000 d 94,434 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-07-28 S 5,000 $23.77 d 304,868 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-07-16 M 5,000 $6.00 a 309,868 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-07-16 M 5,000 d 99,434 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-07-16 S 5,000 $27.36 d 304,868 309,034.00 direct yes

SMITH SANDFORD D - Director

2020-07-15 M 6,667 $6.21 a 6,667 0.00 direct yes

SMITH SANDFORD D - Director

2020-07-15 M 6,667 d 0 0.00 direct yes

SMITH SANDFORD D - Director

2020-07-15 S 6,667 $29.00 d 0 0.00 direct yes

SMITH SANDFORD D - Director

2020-07-10 M 6,667 $6.21 a 6,667 0.00 direct yes

SMITH SANDFORD D - Director

2020-07-10 M 6,667 d 6,667 0.00 direct yes

SMITH SANDFORD D - Director

2020-07-10 S 6,667 $28.00 d 0 0.00 direct yes

MALIK FADY IBRAHAM - Officer EVP RESEARCH & DEVELOPMENT

2020-07-09 S 1,587 $26.96 d 155,034 155,034.00 direct yes

SMITH SANDFORD D - Director

2020-07-08 M 1,434 d 13,334 0.00 direct yes

SMITH SANDFORD D - Director

2020-07-08 M 1,434 $6.21 a 1,434 0.00 direct yes

SMITH SANDFORD D - Director

2020-07-08 S 1,434 $27.00 d 0 0.00 direct yes

SMITH SANDFORD D - Director

2020-07-07 S 5,232 $27.00 d 0 0.00 direct yes

SMITH SANDFORD D - Director

2020-07-07 M 5,232 d 14,768 0.00 direct yes

SMITH SANDFORD D - Director

2020-07-07 S 6,510 $26.00 d 0 0.00 direct yes

SMITH SANDFORD D - Director

2020-07-07 M 5,232 $6.21 a 5,232 0.00 direct yes

SMITH SANDFORD D - Director

2020-07-07 M 6,510 d 0 0.00 direct yes

SMITH SANDFORD D - Director

2020-07-07 M 6,510 $6.72 a 6,510 0.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-07-06 M 5,000 d 104,434 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-07-06 S 5,000 $24.85 d 304,868 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-07-06 M 5,000 $6.00 a 309,868 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-06-24 M 3,821 d 109,434 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-06-24 M 1,179 $6.30 a 306,047 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-06-24 M 1,179 d 0 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-06-24 S 3,821 $23.86 d 304,868 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-06-24 S 1,179 $23.86 d 304,868 309,034.00 direct yes

BLUM ROBERT I - Director - Officer PRESIDENT & CEO

2020-06-24 M 3,821 $6.00 a 308,689 309,034.00 direct yes

COSTA SANTO J - Director

2020-06-22 M 20,000 d 0 0.00 direct

PARSHALL B LYNNE - Director

2020-06-22 M 6,510 d 0 0.00 direct

PARSHALL B LYNNE - Director

2020-06-22 M 6,510 $6.72 a 6,510 0.00 direct

SMITH SANDFORD D - Director

2020-06-22 M 5,000 d 0 0.00 direct

SMITH SANDFORD D - Director

2020-06-22 M 5,000 $4.44 a 5,000 0.00 direct

COSTA SANTO J - Director

2020-06-22 S 20,000 $25.00 d 0 0.00 direct

PARSHALL B LYNNE - Director

2020-06-22 M 10,000 d 0 0.00 direct

PARSHALL B LYNNE - Director

2020-06-22 S 10,000 $25.00 d 0 0.00 direct

SMITH SANDFORD D - Director

2020-06-22 M 5,000 d 5,000 0.00 direct

SMITH SANDFORD D - Director

2020-06-22 S 5,000 $25.00 d 0 0.00 direct

COSTA SANTO J - Director

2020-06-22 M 20,000 $7.61 a 20,000 0.00 direct

PARSHALL B LYNNE - Director

2020-06-22 S 6,510 $25.00 d 0 0.00 direct

PARSHALL B LYNNE - Director

2020-06-22 M 10,000 $4.44 a 10,000 0.00 direct

SMITH SANDFORD D - Director

2020-06-22 S 5,000 $24.00 d 0 0.00 direct

SMITH SANDFORD D - Director

2020-06-22 M 5,000 $4.44 a 5,000 0.00 direct

SMITH SANDFORD D - Director

2020-06-17 M 2,741 d 0 0.00 direct

SMITH SANDFORD D - Director

2020-06-17 M 2,741 $6.84 a 2,741 0.00 direct

SMITH SANDFORD D - Director

2020-06-17 M 4,166 d 0 0.00 direct

SMITH SANDFORD D - Director

2020-06-17 S 4,166 $23.00 d 0 0.00 direct

SMITH SANDFORD D - Director

2020-06-17 S 2,741 $23.00 d 0 0.00 direct

SMITH SANDFORD D - Director

2020-06-17 M 4,166 $6.78 a 4,166 0.00 direct

SMITH SANDFORD D - Director

2020-06-15 M 6,666 $6.30 a 6,666 0.00 direct

SMITH SANDFORD D - Director

2020-06-15 M 6,666 d 0 0.00 direct

SMITH SANDFORD D - Director

2020-06-15 S 6,666 $22.00 d 0 0.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments